California Public Employees Retirement System raised its position in Gossamer Bio Inc (NASDAQ:GOSS) by 119.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,323 shares of the company’s stock after purchasing an additional 12,165 shares during the period. California Public Employees Retirement System’s holdings in Gossamer Bio were worth $375,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently made changes to their positions in GOSS. Rhumbline Advisers raised its holdings in shares of Gossamer Bio by 133.5% in the 3rd quarter. Rhumbline Advisers now owns 55,013 shares of the company’s stock valued at $924,000 after purchasing an additional 31,453 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Gossamer Bio by 39.3% during the 2nd quarter. Royal Bank of Canada now owns 6,967 shares of the company’s stock worth $154,000 after purchasing an additional 1,967 shares during the last quarter. Nuveen Asset Management LLC acquired a new position in shares of Gossamer Bio during the second quarter worth $2,153,000. Victory Capital Management Inc. grew its stake in shares of Gossamer Bio by 12.5% during the second quarter. Victory Capital Management Inc. now owns 968,560 shares of the company’s stock worth $21,483,000 after purchasing an additional 107,960 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Gossamer Bio during the second quarter worth $2,654,000. 61.47% of the stock is currently owned by institutional investors.
Shares of GOSS opened at $24.66 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 13.64 and a quick ratio of 13.64. Gossamer Bio Inc has a 1-year low of $14.49 and a 1-year high of $26.50. The stock has a market cap of $1.63 billion and a PE ratio of -1.09. The firm has a fifty day moving average price of $21.86 and a 200 day moving average price of $20.14.
Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.10). As a group, equities analysts expect that Gossamer Bio Inc will post -3.26 EPS for the current fiscal year.
In other news, major shareholder Faheem Hasnain bought 28,700 shares of the firm’s stock in a transaction that occurred on Wednesday, September 25th. The stock was purchased at an average cost of $2.51 per share, with a total value of $72,037.00. Also, major shareholder Fund V. Gp L.P. Omega sold 82,213 shares of the company’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $21.75, for a total value of $1,788,132.75. Over the last three months, insiders bought 40,821 shares of company stock valued at $275,497 and sold 378,596 shares valued at $8,213,249. 23.30% of the stock is currently owned by insiders.
GOSS has been the topic of several recent analyst reports. Berenberg Bank started coverage on Gossamer Bio in a report on Wednesday, October 30th. They issued a “buy” rating and a $31.00 target price on the stock. Zacks Investment Research downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a report on Tuesday, August 20th. Evercore ISI set a $30.00 price objective on Gossamer Bio and gave the stock a “buy” rating in a research report on Monday, August 12th. ValuEngine downgraded Gossamer Bio from a “buy” rating to a “hold” rating in a report on Wednesday, November 13th. Finally, Bank of America began coverage on Gossamer Bio in a research report on Tuesday. They set a “buy” rating and a $32.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $28.83.
About Gossamer Bio
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2 that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, without nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.
Recommended Story: What is the outlook for the FAANG stocks?
Want to see what other hedge funds are holding GOSS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gossamer Bio Inc (NASDAQ:GOSS).
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.